Dr. Nabanita Nawar is the CEO and co-founder of HDAX Therapeutics. Nabanita has a PhD in medicinal chemistry, and BSc in biological chemistry from University of Toronto. Nabanita’s diverse skillset of 8+ years in drug discovery, leadership, governance, and science policy drives the growth of HDAX through her visionary outlook. She is the “2022 Rising Star” by OICR (Ontario Institute for Cancer research)for leadership and innovation. She has received the Canadian Silver Medal from the Chemical Institute of Canada